Show simple item record

dc.contributor.authorSimon N.Onsongo, KephasOtieno ,Shannenvan Duijn,EmilyAdams,Mervis Omollo,Isdora A.Odero,AlloysK'Oloo,Nathalie Houbene,Emmanuel ,Milimo RobertAroka,Hellen C.Barsosiob,Fredrick Oluoch,Albert Odhiambo,Simon Kariuki,Tobias F. Rinkede Witce
dc.date.accessioned2022-02-16T07:35:26Z
dc.date.available2022-02-16T07:35:26Z
dc.date.issued2022
dc.identifier.urihttps://repository.maseno.ac.ke/handle/123456789/4978
dc.descriptionhttps://doi.org/10.1016/j.diagmicrobio.2021.115591en_US
dc.description.abstractTesting for SARS-CoV-2 in resource-poor settings remains a considerable challenge. Gold standard nucleic acid tests are expensive and depend on availability of expensive equipment and highly trained laboratory staff. More affordable and easier rapid antigen tests are an attractive alternative. This study assessed field performance of such a test in western Kenya. We conducted a prospective multi-facility field evaluation study of NowCheck COVID-19 Ag-RDT compared to gold standard PCR. Two pairs of oropharyngeal and naso pharyngeal swabs were collected for comparative analysis. With 997 enrolled participants the Ag-RDT had a sensitivity 71.5% (63.2-78.6) and specificity of 97.5% (96.2-98.5) at cycle threshold value <40. Highest sensi tivity of 87.7% (77.2-94.5) was observed in samples with cycle threshold values ≤30. NowCheck COVID-19 Ag-RDT performed well at multiple healthcare facilities in an African field setting. Operational specificity and sensitivity were close to WHO-recommended thresholdsen_US
dc.publisherElsevieren_US
dc.subjectSARS COV-2;COVID-19 testing;Point of care testing;Developing countryen_US
dc.titlePerformance of a rapid antigen test for SARS-CoV-2 in Kenyaen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record